Any comments from the "half glass empty" cohort?
Ok, I'll oblige.
Whilst the report is better delivered than previous ... all it says is that no adverse effects have been noted. Dosage is low and only now starting to be increased. While this is all in line with plans ... very little has been achieved so far.
There are no efficacy results or any mention of noted clinical effects..if any. Pipeline stuff.
So all in all a result we all expected. I expect very little action on the SP....wait for the end of day boys.
Must observe though the report is clear and well presented. Now, let's stick to the timeline please....and get those oppies moving.
Ann: MND Trial Successfully Completes First Patient Cohort, page-10
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
-0.015(7.50%) |
Mkt cap ! $90.96M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 18.5¢ | $106.2K | 550.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 714303 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 26750 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |